Ayobami Ogunsola

Dr. Ayobami Ogunsola


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2024 in Cells
Verified
Journal Article
Open access
PDF file
MBMarcel Brown
Marcel Brown
DBDavis James Brady
Davis James Brady
KHkelsey Healy
kelsey Healy
KHKaitlin Henry
Kaitlin Henry
AOAyobami Ogunsola
Ayobami Ogunsola
XMXue Ma
Xue Ma
Bone/fracture healing is a complex process with different steps and four basic tissue layers being affected: cortical bone, periosteum, fascial tissue surrounding the fracture, and bone marrow. Stem cells and their derivatives, including embryonic stem cells, induced pluripotent stem cells, mesenchymal stem cells, hematopoietic stem cells, skeletal stem cells, and multipotent stem cells, can function to artificially introduce highly regenerative cells into decrepit biological tissues and augment the healing process at the tissue level. Stem cells are molecularly and functionally indistinguishable from standard human tissues. The widespread appeal of stem cell therapy lies in its potential benefits as a therapeutic technology that, if harnessed, can be applied in clinical settings. This review aims to establish the molecular pathophysiology of bone healing and the current stem cell interventions that disrupt or augment the bone healing process and, finally, considers the future direction/therapeutic options related to stem cells and bone healing.

9 March 2022 in Sleep Medicine
Verified
Journal Article
Closed access
UMUdeh C. Mercy
Udeh C. Mercy
FEFaith Elenwa
Faith Elenwa
AOAyobami Ogunsola
Ayobami Ogunsola
OEOlatunji A. Eniola
Olatunji A. Eniola
IYIsmaeel Yunusa
Ismaeel Yunusa
IKIbraheem Karaye
Ibraheem Karaye

19 April 2025 in Archives of orthopaedic and trauma surgery
Verified
Journal Article
Open access
PDF file
MBMarcel Brown
Marcel Brown
AOAyobami Ogunsola
Ayobami Ogunsola
MGMatthew S. Gwilt
Matthew S. Gwilt
DBDavis James Brady
Davis James Brady
LGLeslie Granados
Leslie Granados
XMXue Ma
Xue Ma
Introduction: Total Knee Arthroplasty (TKA) is the primary definitive treatment for knee osteoarthritis (OA) and has been essential in helping patients reduce knee pain and regain mobility. There is a need to assess whether various factors such as surgical complications from primary TKA, pre and postoperative range of motion (ROM), Charlson Comorbidity Index (CCI), comorbidities other than CCI, and demographics representative of an outpatient TKA population affect patient-reported outcome measures (PROMs). Materials and methods: Retrospective chart review was performed on 444 patients who underwent TKA at an outpatient surgical facility. Demographics, qualitative, and quantitative measurements were collected at baseline, 4–6 months, and 1-year postoperatively. Patients were stratified by CCI into low (< 2), moderate (2–4), and high (> 4) risk categories. A generalized linear model was used to assess the relationship between time, complications, risk categories, and Knee injury and Osteoarthritis Outcome Score Joint Replacement (KOOS, JR). Results: Majority of patients were women (58.9%), non-Hispanic white (81.9%), categorized as moderate risk CCI (78.8%), with 22.5% experiencing complications post-TKA. KOOS, JR scores improved over time, with an increase of 18.1 points at 4–6 months and 26.1 points at 1-year post-TKA ( p < 0.0001). Surgical complications were linked to a decrease of 3.5 points in KOOS, JR scores, whereas patients with high pre-TKA KOOS, JR scores had an increase of 6.4 points after surgery. Patients who identified as African American experienced an average of 4.7 points lower on KOOS, JR than non-Hispanic whites ( p = 0.0211). High-risk patients (CCI > 4) on average, had higher KOOS, JR scores 12 months after TKA. African Americans and those with surgical complications reported Lower KOOS, JR scores. Conclusions: TKA improved KOOS, JR scores through one year with the greatest improvement in PROM being in higher-risk patients, those without surgical complications. Patients with surgical complications and/or African American race had a lower average KOOS, JR score.

1 February 2024 in Journal of Racial and Ethnic Health Disparities
Verified
Journal Article
Closed access
PDF file
UOUnoma Okoli
Unoma Okoli
AOAyobami Ogunsola
Ayobami Ogunsola
ZAZahira Adeniyi
Zahira Adeniyi
AAAisha Abdulkadir
Aisha Abdulkadir
SDSusan M. DeMetropolis
Susan M. DeMetropolis
IKIbraheem Karaye
Ibraheem Karaye

1 April 2025 in Cannabis & Cannabinoid Research
Verified
Journal Article
Closed access
AOAyobami Ogunsola
Ayobami Ogunsola
SSSamuel Smith
Samuel Smith
EOEniola A. Olatunji
Eniola A. Olatunji
MUMercy C. Udeh
Mercy C. Udeh
IKIbraheem Karaye
Ibraheem Karaye

12 December 2025 in Osteoarthritis and Cartilage Open
Verified
Journal Article
Open access
XMXue Ma
Xue Ma
MBMarcel Brown
Marcel Brown
MGMatthew S. Gwilt
Matthew S. Gwilt
KHKaitlin Henry
Kaitlin Henry
AOAyobami Ogunsola
Ayobami Ogunsola
TSThomas L. Smith
Thomas L. Smith
Evaluate the effect of human placental extract (HPE) on healthy and osteoarthritic articular cartilage. Post-traumatic osteoarthritis (PTOA) rodent model was utilized to assess functional and histologic outcomes of HPE administration at 1, 2 and 3 months. Matrix metalloproteinase (MMP), glycosaminoglycan (GAG) content were assessed via human and porcine cartilage explants exposed to either HPE or saline cohorts. Improved gait function of PTOA-induced rodents treated with HPE in 5 measured parameters, persisting to the 3-month time point against the saline control. No significant difference in medial or lateral joint space was found on MicroCT evaluation after normalizing results to the contralateral uninjured limb. OARSI scores of the medial compartment of PTOA rodents at 3-months showed preservation of cartilage in the HPE-treated cohort with a score of 1.8 for HPE versus 9.17 for saline (p < 0.05). Porcine cartilage explants co-treated with HPE and IL-1 demonstrated marked reduction of MMP-1 (p = 0.001) and MMP-13 (p = 0.0023) expression compared to IL-1 alone. This effect was re-demonstrated in human cartilage with multiple MMP decreased. Reduced levels of GAG release occurred in HPE-treated cartilage explants in comparison to saline control (p = 0.004), with maintenance of structural architecture on histologic preparations. HPE may be a promising treatment for OA by inhibiting the metabolic process of ECM breakdown and preserving the structural integrity of the knee joint in comparison to saline control.